Windlas Biotech's record shows five years of unqualified audit opinions and operating cash flow that consistently exceeds profit. Two things deserve attention: a regulatory suspension of a ₹55 crore product line that the company does not treat as a contingent liability, and a promoter-dominated board whose compensation and ESOP practices have drawn repeated institutional dissent.
Key findings
- A regulatory show-cause notice suspends a ₹55 crore product line, yet the company reports no contingent liabilities
Major- On February 9, 2026, the Uttarakhand Food Safety & Drug Administration issued a show-cause notice temporarily suspending manufacturing of codeine-containing cough syrup, a product line that contributed ₹55.21 crore to FY26 revenue up to that date. The consolidated financial statements state there were no contingent liabilities as of March 31, 2026, while the auditor's statement that no pending litigations would impact the financial position relates to the standalone financial statements. Separately, the company has taken a provision of ₹2.53 crore for state excise duty deposited under protest, as its refund application remains pending. - A promoter family holds four board seats and 83% of equity, while ESOP grants and pay rises draw institutional votes against
Major- Four related promoter-family members sit on the board and together hold 83.48% of equity as of March 31, 2025. Managerial remuneration rose 35.61% in FY26 against 9.07% for non-managerial employees, and the CEO also serves as CFO. The 'Windlas Plan 2025' ESOP scheme, with an exercise price of ₹5 per share, drew 41.30% votes against from public institutions, and ESOP expenses recognised in FY26 jumped to ₹16.61 crore from ₹2.46 crore in FY25. - The sole US subsidiary with negative net worth was dissolved after its only asset was given away without consideration
Minor- Windlas Inc., USA, the group's only subsidiary, was dissolved effective March 31, 2026, with nil turnover and negative net worth of USD -1,923 as of FY25. In FY25, it had assigned its 50% stake in joint venture USpharma Windlas LLC to US Pharma Ltd. without consideration, leaving the group with no remaining subsidiaries, associates, or joint ventures. Title deeds for immovable properties with a gross carrying value of ₹28.29 crore remain in the name of an erstwhile amalgamated entity and are still being transferred. - Operating cash flow covers profit, but a ₹47 crore buyback consumed nearly all free cash flow while a large CWIP balance sits unfunded by debt
Minor- Cumulative operating cash flow of ₹363.85 crore exceeded cumulative profit of ₹281.93 crore over FY21-FY26, and FY26 CFO was ₹105 crore against PAT of ₹66.46 crore. The company completed a ₹47 crore buyback on May 14, 2026, exceeding FY26 free cash flow of ₹37.27 crore. CWIP stood at ₹59.59 crore, representing 32% of gross fixed assets, with no long-term debt drawn to fund it and short-term borrowings of ₹29.88 crore making up 85% of total borrowings. - Revenue recognition is standard, but receivable days are rising and the export business is described as lumpy and binary
Minor- Revenue is recognised ex-factory at a point in time, consistently disclosed across FY22, FY23, and FY26. Receivable days rose from 78.83 in FY24 to 91.81 in FY26, with trade receivables at ₹227 crore against revenue of ₹904 crore. Management describes the export vertical as "binary" where efforts do not always yield revenue, while the top customer contribution declined from 11.7% in FY21 to 6.1% in FY25. - Two FEMA contraventions were self-reported to RBI with a compounding application filed in March 2024
Minor- Windlas Biotech voluntarily filed a compounding application with RBI on March 4, 2024 for contravention of FEMA regulations on receipt and payment of foreign exchange, and for delayed repatriation of dues from its wholly owned subsidiary. No penalties have been imposed by SEBI or stock exchanges in the last three years as of FY26. - Key Audit Matters were reported in every year, not absent
Minor- The auditor reported that the database-level audit trail log managed by a third-party SaaS provider was not made available in FY25 and FY26, while the application-level audit trail operated throughout. The statutory auditor issued unqualified opinions on standalone financial statements and internal financial controls for all five years from FY22 through FY26. Revenue recognition was reported as a Key Audit Matter in each of those years.
What to watch
- Codeine syrup suspension. Resolution of the February 9, 2026 show-cause notice from the Uttarakhand Food Safety & Drug Administration.
- RBI compounding. Outcome of the compounding application filed on March 4, 2024, no status update has been provided through FY26.
- CWIP and capitalisation. Whether the ₹59.59 crore CWIP balance for Plant-6 sees further operating-expense capitalisation in FY27.
- Excise duty refund. Outcome of the refund hearing for ₹2.53 crore deposited under protest, pending as of the FY26 annual report.
Bottom line: This is a disclosed and consistently audited record with cash generation that covers profit every year. The risk sits in two places: a regulatory action against a material product line that the company does not treat as a contingent liability, and a governance structure where promoter control is near-absolute and institutional shareholders have repeatedly objected to compensation decisions. Watch the show-cause notice resolution and the AGM votes.